Physician profile
Amber Charoen
NPI 1508217944
$3,470.18
in general payments reported to CMS, 2019-2025
28 companies · $969 in 2025
The $969 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $157 · 2021: $126 · 2022: $349 · 2023: $375 · 2024: $1,280 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,624.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $834.56 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Abbvie INC. | $482.35 | 2023-2025 | Viberzi, Creon, Linzess |
| Lilly USA, LLC | $390.56 | 2024-2025 | Omvoh |
| Janssen Biotech, INC. | $260.01 | 2020-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $223.26 | 2023-2025 | Trulance, Xifaxan |
| Boston Scientific Corporation | $129.00 | 2020-2022 | |
| Medtronic, INC. | $125.57 | 2021 | |
| Madrigal Pharmaceuticals | $118.96 | 2025 | Rezdiffra |
| Celgene Corporation | $108.53 | 2022-2023 | Zeposia |
| Pfizer INC. | $96.70 | 2019-2025 | |
| Ardelyx, INC. | $80.85 | 2022-2024 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $75.37 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $67.91 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $59.01 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $55.48 | 2022-2023 | Terlivaz |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52.19 | 2019-2023 | Amjevita, Avsola |
| Braintree Laboratories, INC. | $44.23 | 2023-2024 | Suflave, Sutab |
| Genzyme Corporation | $41.14 | 2024 | |
| Phathom Pharmaceuticals, INC. | $41.02 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $40.15 | 2019 | |
| Daiichi Sankyo INC. | $27.41 | 2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.69 | 2023 | Cyltezo |
| Ferring Pharmaceuticals INC. | $19.15 | 2022 | |
| Glaxosmithkline, LLC. | $17.81 | 2019 | |
| Celltrion USA INC. | $15.99 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $15.64 | 2025 | |
| Intercept Pharmaceuticals, INC. | $13.47 | 2024 | |
| Echosens North America, INC. | $12.17 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Charoen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.